Chromosome 12p Amplification in Triple-Negative/

Animals BRCA1 Protein / genetics Carboplatin / pharmacology Cell Line, Tumor Chromosomes, Human, Pair 12 Docetaxel / pharmacology Drug Resistance, Neoplasm / genetics Exome Female Humans Mice Mutation Treatment Outcome Triple Negative Breast Neoplasms / drug therapy Xenograft Model Antitumor Assays

Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
15 08 2019
Historique:
received: 06 12 2018
revised: 05 03 2019
accepted: 07 06 2019
pubmed: 20 6 2019
medline: 17 6 2020
entrez: 20 6 2019
Statut: ppublish

Résumé

Taxanes are the mainstay of treatment in triple-negative breast cancer (TNBC), with

Identifiants

DOI: 10.1158/0008-5472.CAN-18-3835 PMID: 31213465
pubmed: 31213465
pii: 0008-5472.CAN-18-3835
doi: 10.1158/0008-5472.CAN-18-3835
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
Docetaxel 15H5577CQD
Carboplatin BG3F62OND5

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

4258-4270

Subventions

Organisme : Cancer Research UK
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U54 CA224076
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA186784
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA125123
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA226776
Pays : United States

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

Jorge Gómez-Miragaya (J)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain.
ORCID: 0000-0003-1801-4681

Ander Díaz-Navarro (A)

Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), CIBERONC, Universidad de Oviedo, Oviedo, Spain.
ORCID: 0000-0001-6808-4800

Raul Tonda (R)

CNAG-CRG, Centre for Genomic Regulation (CRG), Institute of Science and Technology (BIST), Centre for Genomic Analysis (CNAG), Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.
ORCID: 0000-0001-7893-2404

Sergi Beltran (S)

CNAG-CRG, Centre for Genomic Regulation (CRG), Institute of Science and Technology (BIST), Centre for Genomic Analysis (CNAG), Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.

Luis Palomero (L)

Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.

Marta Palafox (M)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain.

Lacey E Dobrolecki (LE)

Departments of Molecular and Cellular Biology and Radiology, The Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.

Chen Huang (C)

Departments of Molecular and Human Genetics, The Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.

Suhas Vasaikar (S)

Departments of Molecular and Human Genetics, The Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.

Bing Zhang (B)

Departments of Molecular and Human Genetics, The Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
ORCID: 0000-0001-8676-2425

Gerburg M Wulf (GM)

Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Alejandro Collado-Sole (A)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain.

Eva M Trinidad (EM)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain.
ORCID: 0000-0001-6090-5205

Purificación Muñoz (P)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain.
ORCID: 0000-0002-3751-2099

Laia Paré (L)

Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.

Aleix Prat (A)

Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Department of Medical Oncology, Hospital Clinic, Barcelona, Spain.

Alejandra Bruna (A)

Cancer Research UK Cancer Centre, Cambridge Biomedical Campus, Cambridge, United Kingdom.

Carlos Caldas (C)

Cancer Research UK Cancer Centre, Cambridge Biomedical Campus, Cambridge, United Kingdom.

Joaquín Arribas (J)

Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
ORCID: 0000-0002-0504-0664

María Teresa Soler-Monso (MT)

Pathology Department, University Hospital of Bellvitge, IDIBELL, Barcelona, Spain.

Anna Petit (A)

Pathology Department, University Hospital of Bellvitge, IDIBELL, Barcelona, Spain.

Judith Balmaña (J)

Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

Cristina Cruz (C)

Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
ORCID: 0000-0002-6474-7504

Violeta Serra (V)

Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
ORCID: 0000-0001-6620-1065

Miguel Angel Pujana (MA)

Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
ORCID: 0000-0003-3222-4044

Michael T Lewis (MT)

Departments of Molecular and Cellular Biology and Radiology, The Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.

Xose S Puente (XS)

Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), CIBERONC, Universidad de Oviedo, Oviedo, Spain.
ORCID: 0000-0001-9525-1483

Eva González-Suárez (E)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain. egsuarez@idibell.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chromosome 12p Amplification in Triple-Negative/
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Protéine BRCA1 › Chromosome 12p Amplification in Triple-Negative/
questionsmedicales.fr › Composés chimiques organiques › Complexes de coordination › Carboplatine › Chromosome 12p Amplification in Triple-Negative/
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Chromosome 12p Amplification in Triple-Negative/
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Chromosomes › Chromosomes de mammifère › Chromosomes humains › Chromosomes humains 6-12 et X › Chromosomes humains de la paire 12 › Chromosome 12p Amplification in Triple-Negative/
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Diterpènes › Taxoïdes › Docetaxel › Chromosome 12p Amplification in Triple-Negative/
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › Chromosome 12p Amplification in Triple-Negative/
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Exome › Chromosome 12p Amplification in Triple-Negative/
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Chromosome 12p Amplification in Triple-Negative/
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Chromosome 12p Amplification in Triple-Negative/
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Chromosome 12p Amplification in Triple-Negative/
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Chromosome 12p Amplification in Triple-Negative/
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Tumeurs du sein triple-négatives › Chromosome 12p Amplification in Triple-Negative/
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › Chromosome 12p Amplification in Triple-Negative/